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The carbonic anhydrases (CA, EC 4.2.1.1) are abundant zinc metalloenzymes found in a diversity of organisms including higher vertebrates, green plants, algae, bacteria and archaea. 1 In humans 15 different CA isozymes (designated hCA) belonging to the α-CA class are presently known; they exhibit variable enzyme kinetics, tissue distribution, expression levels and subcellular locations. [1] [2] [3] [4] Many of these isozymes are quite recent discoveries cf. the physiologically abundant and widely distributed isozymes hCA I and hCA II (known since the 1930s, with isozymes acknowledged in the 1960s) and many have shown promise as druggable targets through inhibition of their catalytic activity, which may elicit desirable, yet variable physiological responses. [1] [2] [3] [4] The key challenge that confronts medicinal chemists in the quest to deliver CA based therapies or diagnostics has thus widened from designing potent CA inhibitors (now relatively 'simple' owing to the prolific efforts of researchers over several decades 5 ) -to include the broader challenge of discovering isozyme selective inhibitorseither by drug design and/or drug delivery mechanisms. The classical recognition motif for small molecules to bind the active site of CA is an aromatic sulfonamide moietyArSO 2 NH 2 . [1] [2] [3] [4] [5] [6] The deprotonated sulfonamide moiety (ArSO 2 NH -) coordinates to the CA active site Zn 2+ and so inhibits the catalytic ability of the enzyme. This CA recognition moiety exhibits remarkable reliability in anchoring the inhibitor molecule within the CA active site such that tethering groups to this CA recognition pharmacophore has made for an effective means to incorporate and also optimise desirable chemical properties of sulfonamide CA inhibitors. 5 Transmembrane hCAs -isozymes IX, XII and XIV 7-9 -like other hCAs regulate pH and carbon dioxide (CO 2 ):bicarbonate anion (HCO 3 -) homeostasis, through catalysis of the reversible hydration of CO 2 to give HCO 3 -and a proton (H + ). An additional feature that distinguishes the transmembrane isozymes from most other CAs is that their CA catalytic domain is located in the extracellular (rather than intracellular) space. The expression level of isozymes hCA IX and XII is elevated in response to hypoxia and research on the involvement of these isozymes in cancer has progressed considerably in recent years, particularly for hCA IX. [9] [10] [11] [12] [13] It has been confirmed that hCA IX is a high activity CA isozyme responsible for the extracellular acidification (pH e ) of the tumor microenvironment. Multiple downstream effects of this reduced pH e are associated with tumor progression and poor prognosis. 11, 12 Aromatic sulfonamide compounds have been shown to reverse the effect of tumor acidification; to 4 inhibit the growth of cancer cells and to suppress tumor invasion mediated by these CAs. [9] [10] [11] [12] [13] Thus the data from these many physiological studies appear to have identified a CA mediated, hypoxic tumor specific pathway. This provides firm grounds for exploring the effects of this class of compound as a novel approach to discriminate between healthy cells and cancerous cells, specifically targeting hypoxic tissues -an attractive attribute that is lacking in many existing cancer therapies. 14, 15 In addition to a potential role in cancer, it was recently determined that hCA XII is highly expressed in the eyes of glaucoma patients. 16 Current antiglaucoma drugs were thought to target hCA II and IV, but hCA XII may in part be responsible for the intraocular pressure effects of clinically used sulfonamides and further research on the role of isozyme XII in glaucoma therapies is necessary to verify.
hCA XIV is a low activity CA isozyme 17 The CA inhibition data against all three of these membrane-associated CA isozymes has so far been reported for only a small number of sulfonamide derivatives, all of which are quite simple with respect to 'tail' groups. 17 The inhibition trends are variable, rather than clustered, this indicating that the selective inhibition of these isozymes may indeed be possible. It is however clearly apparent that a more exhaustive investigation of this CA-subclass with a larger number of inhibitors of varying tails will be required to deliver such an outcome.
The physiological roles for the transmembrane associated CA isozymes in cancer and possibly other disease states provides the impetus to investigate the inhibition of these 5 isozymes to develop compounds that can discriminate them from the physiologically dominant, cytosolic hCA I and II. The preparation of aromatic sulfonamide inhibitors with an impaired ability to diffuse through lipid membranes is one possible means by which to target these isozymes. It is noteworthy that attention from the pharmaceutical industry for carbohydrate-based drugs is not prevalent in comparison with more traditional small organic molecules. The degree of oral bioavailability of glycoconjugates is compromised (they violate Lipinksi's 'Rule of 5' 22 ) by the poor ability of sugars to diffuse across cell membranes, however oral bioavailability is not always a primary consideration as there are other routes for drug administration (eg. intravenous), drug transporting and specifically for transmembrane
CAs an extracellular location of the drug target. We have recently demonstrated the versatility of the 1,3-dipolar cycloaddition reaction 'click-tailing' synthetic methodology to readily generate 1,4-disubstituted-1,2,3-triazole glycoconjugates 3-30 from azido sugars a-g and sulfonamide-alkyne scaffolds 1 and 2 (Scheme 1). 23, 24 All compounds were synthesized as reported earlier by this group. 23 Compounds 3-30 (each with a sugar tail) were very effective inhibitors of the high activity transmembrane isozyme hCA IX, and importantly for some compounds selectivity for CA IX over I and II was observed. 23 Our results with hCA IX have encouraged us to further investigate the inhibition properties of these glycoconjugates at the remaining two transmembrane hCA isozymes XII and XIV, these results are reported here. hCA II, IX XII and XIV enzyme inhibition data for parent scaffolds 1 and 2, glycoconjugate compound library 3-30 and standard CA inhibitors are reported in Table 1 , data for hCA XII and XIV being reported for the first time here. CA inhibition against these isozymes was determined by assaying the CA catalyzed hydration of CO 2 . 25 Inhibition data against the other physiologically dominant isozyme hCA I has been reported previously 23 and is not included in Table 1 for clarification of presentation -however for reference 1-30 are typically micromolar inhibitors at this isozyme such that selectivity of transmembrane isozymes against this isozyme is for most compounds 2-3 orders of magnitude (the only exceptions are 14 and 22, with nanomolar hCA I K i s of 7.7 and 9.6 nM, respectively). Clinically used aromatic sulfonamides that are CA inhibitors include acetazolamide (AZA), methazolamide (MZA), ethoxazolamide (EZA), brinzolamide (BRZ), dorzolamide (DRZ) and dichlorophenamide (DCP). [1] [2] [3] [4] The assembly of CA inhibition data for these sulfonamides against hCA IX, XII and XIV was recently completed 17 and demonstrates they are quite effective inhibitors (mid-low nM) against these isozymes, generally with slightly higher inhibition at hCA XII compared to hCA IX and XIV ( Table 1 All glycoconjugates also had some selectivity for hCA XII compared to XIV -the only exception being compound 4 which was ~equipotent at these isozymes. Conservation of active site structure and topology within the CA enzyme family has made it challenging to target subtle isozyme differences, however to maximise the benefits of any future therapies involving CA inhibition, it is essential to develop isozyme-specific compounds. Here we have explored a library of benzenesulfonamides with triazole-tethered carbohydrate tails against the transmembrane subclass of CAs -hCA IX, XII and XIV. The qualitative structure-activity demonstrated that the stereochemical diversity within the carbohydrate tails effectively interrogated the CA active site topology, generating many potent inhibitors with a range of isozyme selectivity profiles -an important outcome in the quest for potential cancer therapy applications. Sugar tails have therefore shown promise as a valuable approach to solubilize the aromatic sulfonamide pharmacophore and target it to extracellular CA domains as well as to deliver isozyme differentiation.
